Loading...
XNAS
DOMH
Market cap62mUSD
Dec 05, Last price  
3.89USD
1D
-7.16%
1Q
-33.50%
Name

Dominari Holdings Inc

Chart & Performance

D1W1MN
XNAS:DOMH chart
P/E
—
P/S
3.43
EPS
—
Div Yield, %
—
Shrs. gr., 5y
111.03%
Rev. gr., 5y
358.04%
Revenues
18m
+789.95%
23,045,65724,838,174154,6981,025,9611,359,1101,432,452820,92519,92227,00010,00033,000877,0001,236,00028,0009,0000002,039,00018,146,000
Net income
-15m
L-35.74%
-2,848,7483,512,881-938,374-4,135,534-9,148,631-7,736,242-3,461,640-3,857,024-17,965,000-30,532,000-51,465,000-6,476,000-3,306,0001,727,000-4,183,000-12,337,000-6,919,000-38,568,000-22,882,000-14,703,000
CFO
-15m
L-32.00%
-525,7406,657,657-8,628,614-6,409,255-7,832,625-8,693,195-4,359,660-3,815,687-5,270,000-9,516,000-4,620,00070,000-3,272,000-2,729,000-3,017,000-4,021,000-6,603,000-10,597,000-22,232,000-15,118,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.
URL
https://aikidopharma.com/
IPO date
Mar 18, 1980
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT